Drugs that made headlines in 2016

Gene therapies featured prominently among this year's newsworthy drugs, some of which have already received a green light from regulatory agencies for sale or are otherwise surging forward in trials. Other drugs ended the year with a much less rosy efficacy or safety profile.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2016-12, Vol.22 (12), p.1377-1379
1. Verfasser:	Keener, Amanda B.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/433 692/308/153 692/700/565/201 Biological products industry Biomedical and Life Sciences Biomedicine Cancer Research Clinical Trials as Topic Drug Approval Drug Discovery Drug Industry - trends Drug Therapy Drugs Europe Gene therapy Genetic Therapy Health Policy Humans Infectious Diseases Metabolic Diseases Molecular Medicine Muscular Atrophy, Spinal - drug therapy Neurosciences news Nucleotides - chemistry Nusinersen Pembrolizumab Pharmaceutical industry Pharmaceutical Preparations Product development Safety Testing United States United States Food and Drug Administration Venetoclax
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Gene therapies featured prominently among this year's newsworthy drugs, some of which have already received a green light from regulatory agencies for sale or are otherwise surging forward in trials. Other drugs ended the year with a much less rosy efficacy or safety profile.
ISSN:	1078-8956 1546-170X
DOI:	10.1038/nm1216-1377